US4284773A - 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones - Google Patents

1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones Download PDF

Info

Publication number
US4284773A
US4284773A US06/066,113 US6611379A US4284773A US 4284773 A US4284773 A US 4284773A US 6611379 A US6611379 A US 6611379A US 4284773 A US4284773 A US 4284773A
Authority
US
United States
Prior art keywords
sub
carbon atoms
hydrogen atom
alkyl group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/066,113
Inventor
Fumiyoshi Ishikawa
Shinichiro Ashida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
Original Assignee
Daiichi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd filed Critical Daiichi Pharmaceutical Co Ltd
Assigned to DAIICHI SEIYAKU CO., LTD. reassignment DAIICHI SEIYAKU CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: ASHIDA SHINICHIRO, ISHIKAWA FUMIYOSHI
Application granted granted Critical
Publication of US4284773A publication Critical patent/US4284773A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • This invention relates to 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones represented by the formula (I): ##STR2## wherein one of Z 1 , Z 2 and Z 3 is a sulfur atom and the remaining two of Z 1 , Z 2 and Z 3 represent CH, R 1 and R 2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together R 1 and R 2 represent an alkylene chain of 3 to 5 carbon atoms, R 3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and the pharmaceutically acceptable acid addition salts thereof.
  • the partial structure ##STR6## includes the following three types of condensed ring, i.e., ##STR7## which are designated as thieno[2,3-d]pyrimidine (A), thieno[3,4-d]pyrimidine (B) or thieno[3,2-d]pyrimidine (C), respectively.
  • the compounds of the formula (I) are tetracyclic compounds.
  • R 1 and R 2 jointly forms a tetramethylene group --CH 2 ) 4 in the case of thieno[2,3-d]pyrimidines (the partial structure (A) above)
  • the compound can be represented by the formula: ##STR8## which is designated as 1,2,3,5,6,7,8,9-octahydroimidazo[1,2-a][1]benzothieno[2,3-d]pyrimidin-2-one (Compound 8, hereinafter described).
  • the compounds of the present invention represented by the formula (I) can exist in several possible tautomeric forms, e.g.: ##STR9## wherein R 1 , R 2 , R 3 , Z 1 , Z 2 and Z 3 are as defined above.
  • the compounds of the present invention represented by the formula (I) can be prepared according to the following reaction scheme: ##STR10## wherein Z 1 , Z 2 , Z 3 , R 1 , R 2 and R 3 are as defined above, and X 1 , X 2 and X 3 each represents a chlorine atom or a bromine atom and R 4 represents a lower alkyl group.
  • the resulting compound of the formula (III) is then reacted with an ⁇ -haloalkanoic acid alkyl ester, e.g., ethyl bromoacetate, ethyl ⁇ -bromopropionate and the like, in an inert organic solvent such as acetone, methyl ethyl ketone and the like in the presence of an acid acceptor such as powdered potassium carbonate or sodium carbonate in an inert gas atmosphere, i.e., nitrogen or argon, while heating at a temperature of about 25° C.
  • an ⁇ -haloalkanoic acid alkyl ester e.g., ethyl bromoacetate, ethyl ⁇ -bromopropionate and the like
  • an inert organic solvent such as acetone, methyl ethyl ketone and the like
  • an acid acceptor such as powdered potassium carbonate or sodium carbonate in an inert gas atmosphere, i.
  • the pharmaceutically acceptable acid addition salts of the compounds represented by the formula (I) can be easily prepared by adding a selected nontoxic acid to a methanolic solution of the compound (I).
  • suitable examples of pharmaceutically acceptable nontoxic acid addition salts are hydrochloride, hydrobromide, alkyl- or arylsulfonate, phosphate, sulfate, fumarate, maleate, succinate, tartarate, citrate and other non-toxic acid salts which are commonly used in the art.
  • the compounds of the present invention have unique properties as blood platelet anti-aggregatory agents. These compounds are useful in the prevention of intravascular thrombosis, prevention of coronary thrombosis, prevention of transient ischemic episodes, prevention of platelet thrombosis in the use of prosthetic devices (artificial heart valves, etc.) and other thrombotic complications including thromboangitis obliterans, etc.
  • optionally substituted imidazo[2,1-b]quinazolines reported by Beverung et al have a potent hypotensive activity which is undesirable side effect for anticlotting therapy.
  • the compounds of the present invention do not have a hypotensive activity and more potent blood platelet antiaggregatory activity than imidazo[2,1-b]quinazolines.
  • a methanolic solution of the test compound was added to the PRP, then aggregation was induced by adding to the mixture of ADP solution containing CaCl 2 or a collagen suspension prepared according to the method described by Ashida et al [S. Ashida and Y. Abiko, Thromb. Diath. Haemorrh., 30, 528 (1975)], and the optical density of the resulting mixture was determined. Control was made by addition of methanol instead of the above methanolic solution of the test compound, and the optical density of the resulting mixture was also determined, which showed 100% aggregation. A dose response curve was drawn from the results obtained above and the effective concentration giving a 50% inhibition (EC 50 ) was calculated.
  • the blood pressure of normal rat was measured at 5-6 hours after the oral administration at a dose of 50 mg/kg.
  • a suitable dosage level for oral administration can range from about 0.5 to about 30 mg/kg in single or multiple doses along with an appropriate pharmaceutically acceptable carrier and diluent in the form of a tablet, a capsule or powder, if desired.
  • the preferred dosage level of the compounds of the invention for adult human is in the range of about 10 to about 200 mg/day.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A 1,2,3,5-tetrahydroimidazothienopyrimidin-2-one represented by the formula: ##STR1## wherein one of Z1, Z2 and Z3 is a sulfur atom and the remaining two of Z1, Z2 and Z3 represent CH, R1 and R2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together R1 and R2 represent an alkylene chain of 3 to 5 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof, which exhibit an excellent blood platelet anti-aggregatory activity and are useful as anti-thrombotic agents.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to 1,2,3,5-tetrahydroimidazothienopyrimidin-2-ones represented by the formula (I): ##STR2## wherein one of Z1, Z2 and Z3 is a sulfur atom and the remaining two of Z1, Z2 and Z3 represent CH, R1 and R2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together R1 and R2 represent an alkylene chain of 3 to 5 carbon atoms, R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and the pharmaceutically acceptable acid addition salts thereof.
2. Description of the Prior Art
Hitherto, anti-thrombotic agents having an imidazopyrimidine structure have been reported in literatures. For example, W. N. Beverung et al, U.S. Pat. No. 3,932,407 discloses 1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-ones represented by the formula: ##STR3## wherein R1 represents a hydrogen atom or an alkyl group, and R2 and R3 each represents a hydrogen atom, an alkyl group or a halogen atom. However, these compounds have not proved satisfactory for clinical use in preventing thrombosis because of their side effects such as hypotensive activity.
P. Blaskiewicz et al, German Offenlegungsschrift No. 2,411,273 discloses the compounds represented by the formula: ##STR4## but this compound is reported as having an anti-inflammatory activity. Also, C. F. Sauter et al, Monatsh. Chem., 109, 53 (1978) discloses the compounds having the formula: ##STR5## wherein R1 and R2 each represents --CH3 or, when taken together, R1 and R2 represent --CH2 CH2 CH2 CH2 --, but blood platelet antiaggregatory activity is not reported for the above compounds.
DETAILED DESCRIPTION OF THE INVENTION
In the formula (I) above, the partial structure ##STR6## includes the following three types of condensed ring, i.e., ##STR7## which are designated as thieno[2,3-d]pyrimidine (A), thieno[3,4-d]pyrimidine (B) or thieno[3,2-d]pyrimidine (C), respectively.
When R1 and R2 jointly represent an alkylene chain, the compounds of the formula (I) are tetracyclic compounds. For example, when R1 and R2 jointly forms a tetramethylene group --CH2)4 in the case of thieno[2,3-d]pyrimidines (the partial structure (A) above), the compound can be represented by the formula: ##STR8## which is designated as 1,2,3,5,6,7,8,9-octahydroimidazo[1,2-a][1]benzothieno[2,3-d]pyrimidin-2-one (Compound 8, hereinafter described).
The compounds of the present invention represented by the formula (I) can exist in several possible tautomeric forms, e.g.: ##STR9## wherein R1, R2, R3, Z1, Z2 and Z3 are as defined above.
It should be also noted that all the possible optically active and inactive compounds are included in the scope of the compounds of the present invention represented by the formula (I) above wherein R3 represents an alkyl group.
The compounds of the present invention represented by the formula (I) can be prepared according to the following reaction scheme: ##STR10## wherein Z1, Z2, Z3, R1, R2 and R3 are as defined above, and X1, X2 and X3 each represents a chlorine atom or a bromine atom and R4 represents a lower alkyl group.
As seen in the above reaction scheme, a 2,4-dihalothienopyrimidine having the formula (II) is reduced with an alkali metal borohydride such as sodium borohydride, lithium borohydride and the like, preferably with sodium borohydride, in an inert organic solvent such as methanol, ethanol, chloroform, aqueous tetrahydrofuran or a mixture thereof at a temperature of about 25° to about 100° C. for about one hour to overnight (about 16 hours) to give a 2-halo-3,4-dihydrothienopyrimidine represented by the formula (III) in high yield. The resulting compound of the formula (III) is then reacted with an α-haloalkanoic acid alkyl ester, e.g., ethyl bromoacetate, ethyl α-bromopropionate and the like, in an inert organic solvent such as acetone, methyl ethyl ketone and the like in the presence of an acid acceptor such as powdered potassium carbonate or sodium carbonate in an inert gas atmosphere, i.e., nitrogen or argon, while heating at a temperature of about 25° C. to about 100° C., preferably at refluxing temperature, with vigorous stirring for a period of about 1 to about 48 hours to give a 2-halo-3-α-alkoxycarbonylalkyl-3,4-dihydrothienopyrimidine represented by the formula (IV). The resulting compound (IV) is then heated with ammonia in an alcohol such as methanol or ethanol at a temperature of about 100° to about 150° C., preferably 120° C. to 130° C., for about 2 to about 16 hours in a sealed tube filled with an inert gas, e.g., nitrogen or argon, to obtain the desired compound of the formula (I).
The pharmaceutically acceptable acid addition salts of the compounds represented by the formula (I) can be easily prepared by adding a selected nontoxic acid to a methanolic solution of the compound (I). Suitable examples of pharmaceutically acceptable nontoxic acid addition salts are hydrochloride, hydrobromide, alkyl- or arylsulfonate, phosphate, sulfate, fumarate, maleate, succinate, tartarate, citrate and other non-toxic acid salts which are commonly used in the art.
The synthesis of the compounds of the present invention is further illustrated by the following Synthesis Examples. Unless otherwise indicated, all parts, percents, ratios and the like are by weight.
SYNTHESIS EXAMPLE 1 Preparation of 2-chloro-5,6-dimethyl-3,4-dihydrothieno[2,3-d]pyrimidine (Compound 1A of Formula III)
To a solution of 4.66 g of 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine in 150 ml of ethanol-chloroform (1:1 by volume) was slowly added 2.32 g of sodium borohydride with stirring. The mixture was stirred at room temperature for 6 hours and the solvent removed in vacuo. To the solid residue was added 50 ml of water and the insoluble material was filtered, washed with water, dried, and recrystallized from benzene to give 2.05 g of 2-chloro-5,6-dimethyl-3,4-dihydrothieno[2,3-d]pyrimidine, mp 170°-172° C.
Elemental Analysis:
Calc'd for C8 H9 ClN2 S: C, 47.88; H, 4.52; N, 13.96; Found: C, 47.73; H, 4.47; N, 13.88.
SYNTHESIS EXAMPLE 2
In the same manner as described in Example 1 but using an equimolar amount of a substituted 2,4-dichlorothienopyrimidine having the formula (II) in place of the 2,4-dichloro-5,6-dimethylthieno[2,3-d]pyrimidine used in Example 1, the following substituted 2-halo-3,4-dihydrothienopyrimidine compounds (Compounds 2A to 17A) having the formula (III) were produced. In this example, the reaction was carried out at a temperature of 40° to 50° C. for Compounds 5A, 7A, 8A, 15A and 17A, at a temperature of 50° to 60° C. for Compound 9A, at a temperature of 40°-45° C. for Compound 16A and at room temperature for the remaining compounds.
__________________________________________________________________________
 ##STR11##                           (III)                                
Compound                                                                  
No.   Z.sub.1                                                             
         Z.sub.2                                                          
            Z.sub.3                                                       
               X.sub.1                                                    
                 R.sub.1                                                  
                        R.sub.2                                           
                             mp (°C.)*                             
__________________________________________________________________________
2A    CH CH S  Cl                                                         
                 5-H    6-H  146-148 (dec)                                
3A    CH CH S  Cl                                                         
                 5-H    6-CH.sub.3                                        
                             130-140[195-200(dec.)]                       
4A    CH CH S  Cl                                                         
                 5-CH.sub.3                                               
                        6-H  156-159 (dec)                                
5A    CH CH S  Cl                                                         
                 5-Cl   6-CH.sub.3                                        
                             172-174 (dec)                                
6A    CH CH S  Cl                                                         
                 5-CH.sub.3                                               
                        6-Cl 140-160[227-230(dec.)]                       
7A    CH CH S  Cl                                                         
                 (CH.sub.2).sub.3                                         
                             151-153 (dec)                                
8A    CH CH S  Cl                                                         
                 (CH.sub.2).sub.4                                         
                             140-142 (dec)                                
9A    CH CH S  Cl                                                         
                 (CH.sub.2).sub.5                                         
                             143-145 (dec)                                
10A   CH CH S  Cl                                                         
                 5-C.sub.6 H.sub.5                                        
                        6-H  147-148 (dec)                                
11A   S  CH CH Cl                                                         
                 6-H    7-H  138-140 (dec)                                
12A   S  CH CH Cl                                                         
                 6-CH.sub.3                                               
                        7-H  120-125[158-166(dec.)]                       
13A   CH S  CH Cl                                                         
                 5-H    7-H  151-153                                      
14A   CH S  CH Cl                                                         
                 5-CH.sub.3                                               
                        7-H  168-171                                      
15A   CH CH S  Cl                                                         
                 5-C.sub.3 H.sub.7                                        
                        6-C.sub.2 H.sub.5                                 
                             unclear                                      
16A   CH CH S  Cl                                                         
                 5-CH.sub.3                                               
                        6-C.sub.3 H.sub.7                                 
                             unclear                                      
17A   CH CH S  Cl                                                         
                 5-CH.sub.3                                               
                        6-C.sub.5 H.sub.11                                
                             unclear                                      
__________________________________________________________________________
 *Generally, these compounds do not give clear melting or decomposing poin
 because of the instability under heating. That is, upon heating these    
 compounds gradually become wet and then solidified followed by           
 decomposition. The figure in bracket [ ] means the decomposing point afte
 the solidification.
SYNTHESIS EXAMPLE 3 Preparation of 6,7-dimethyl-1,2,3,5-tetrahydroimidazo[1,2-a]thieno[2,3-d]pyrimidine-2-one (Compound 1 of Formula I)
A mixture of 6.0 g of 2-chloro-5,6-dimethyl-3,4-dihydrothieno[2,3-d]pyrimidine, 5.52 g of ethyl bromoacetate and 12.5 g of powdered potassium carbonate in 300 ml of methyl ethyl ketone was heat-refluxed with stirring under a nitrogen atmosphere for 4 hours. After cooling, an insoluble inorganic salt was filtered off and the filtrate was concentrated in vacuo to give a crude oil of 2-chloro-3-ethoxycarbonylmethyl-5,6-dimethyl-3,4-dihydrothieno[2,3-d]pyrimidine. Because of the instability of the resulting compound, the crude oil was used in the subsequent reaction.
A mixture of the crude oil obtained above in 50 ml of 10% ammonia-ethanol solution was heated in a sealed tube at 120°-130° C. in an oil bath for 5 hours. After cooling, the precipitated crystals were filtered, washed with water and dried to give 3.0 g of 6,7-dimethyl-1,2,3,5-tetrahydroimidazo[1,2-a]thieno[2,3-d]pyrimidin-2-one. The hydrochloride salt of the resulting compound was prepared by reacting the free compound with hydrochloric acid in methanol in a usual manner and had a melting point of 249°-255° C. (with decomposition).
Elemental Analysis:
Calc'd for C10 H12 ClN3 O: C, 46.60; H, 4.69; N, 16.30; Found: C, 46.66; H, 4.61; N, 16.29.
SYNTHESIS EXAMPLE 4
In the same manner as described in Example 3 but using an equimolar amount of a substituted 2-halo-3,4-dihydrothienopyrimidine prepared in Example 2 in place of the 2-chloro-5,6-dimethyl-3,4-dihydrothieno[2,3-d]pyrimidine (1A) used in Example 3, the following compounds (Compounds 2 to 17) of the formula (I) were obtained.
__________________________________________________________________________
 ##STR12##                                                                
                                          Elemental Analysis              
                         Melting*         Found Values                    
Comp.                    Point                                            
                              Empirical   (calc'd values in bracket)      
No. Z.sub.1                                                               
       Z.sub.2                                                            
          Z.sub.3                                                         
             R.sub.1                                                      
                 R.sub.2                                                  
                      R.sub.3                                             
                         (°C.)                                     
                              Formula     C    H    N                     
__________________________________________________________________________
2   CH CH S  6-H 7-H  H  200  C.sub.8 H.sub.8 ClN.sub.3 OS                
                                          41.62                           
                                               3.42                       
                                                   18.55                  
                         (dec.)           (41.83                          
                                               3.51                       
                                                   18.30)                 
3   CH CH S  6-H 7-CH.sub.3                                               
                      H  233-235                                          
                              C.sub.9 H.sub.10 ClN.sub.3 OS               
                                          44.17                           
                                               4.08                       
                                                   17.39                  
                         (dec.)           (44.35                          
                                               4.14                       
                                                   17.24)                 
4   CH CH S  6-CH.sub.3                                                   
                 7-H  H  252-257                                          
                              C.sub.9 H.sub.10 ClN.sub.3 OS . 1/2 H.sub.2 
                              O           42.69                           
                                               3.98                       
                                                   16.77                  
                         (dec.)           (42.78                          
                                               4.38                       
                                                   16.63)                 
5   CH CH S  6-Cl                                                         
                 7-CH.sub.3                                               
                      H  241-243                                          
                              C.sub.9 H.sub.9 Cl.sub.2 N.sub.3 OS . 1/2   
                              H.sub.2 O   37.38                           
                                               3.47                       
                                                   14.69                  
                         (dec.)           (37.64                          
                                               3.51                       
                                                   14.63)                 
6   CH CH S  6-CH.sub.3                                                   
                 7-Cl H  220- C.sub.9 H.sub.9 Cl.sub.2 N.sub.3 OS         
                                          39.16                           
                                               3.47                       
                                                   15.12                  
                         (dec.)           (38.86                          
                                               3.26                       
                                                   15.11)                 
7   CH CH S  (CH.sub.2).sub.3                                             
                      H  250- C.sub.11 H.sub.12 ClN.sub.3 OS              
                                          49.11                           
                                               3.86                       
                                                   15.87                  
                         (dec.)           (48.98                          
                                               4.49                       
                                                   15.58)                 
8   CH CH S  (CH.sub.2).sub.4                                             
                      H  257-259                                          
                              C.sub.12 H.sub.14 ClN.sub.3 OS              
                                          50.87                           
                                               4.93                       
                                                   14.93                  
                         (dec.)           (50.79                          
                                               4.97                       
                                                   14.81)                 
9   CH CH S  (CH.sub.2).sub.5                                             
                      H  132-138                                          
                              C.sub.14 H.sub.16 ClN.sub.3 OS              
                                          52.43                           
                                               5.35                       
                                                   14.38                  
                         (dec.)           (52.43                          
                                               5.42                       
                                                   14.11)                 
10  CH CH S  6-C.sub.6 H.sub.5                                            
                 7-H  H  233-234                                          
                              C.sub.14 H.sub.12 ClN.sub.3 OS              
                                          54.79                           
                                               4.22                       
                                                   14.02                  
                         (dec.)           (55.00                          
                                               3.96                       
                                                   13.74)                 
11  S  CH CH 7-H 8-H  H  >280 C.sub.8 H.sub.8 ClN.sub.3 OS                
                                          42.20                           
                                               3.48                       
                                                   18.67                  
                                          (41.83                          
                                               3.51                       
                                                   18.30)                 
12  S  CH CH 7-CH.sub.3                                                   
                 8-H  H  >280 C.sub.9 H.sub.10 ClN.sub.3 OS               
                                          44.10                           
                                               4.46                       
                                                   17.12                  
                                          (44.35                          
                                               4.14                       
                                                   17.24)                 
13  CH S  CH 6-H 8-H  H  262-264                                          
                              C.sub.8 H.sub.8 ClN.sub.3 OS                
                                          41.70                           
                                               3.47                       
                                                   18.50                  
                         (dec.)           (41.83                          
                                               3.51                       
                                                   18.30)                 
14  CH S  CH 6-CH.sub.3                                                   
                 8-H  H  >280 C.sub.9 H.sub.10 ClN.sub.3 OS               
                                          44.49                           
                                               4.17                       
                                                   17.74                  
                                          (44.35                          
                                               4.14                       
                                                   17.24)                 
15  CH CH S  6-C.sub.3 H.sub.7                                            
                 7-C.sub.2 H.sub.5                                        
                      H  214-216                                          
                              C.sub.13 H.sub.18 ClN.sub.3 OS              
                                          51.67                           
                                               5.96                       
                                                   14.03                  
                         (dec.)           (52.08                          
                                               6.05                       
                                                   14.02)                 
16  CH CH S  6-CH.sub.3                                                   
                 7-C.sub.3 H.sub.7                                        
                      H  209-212                                          
                              C.sub.12 H.sub.16 ClN.sub.3 OS              
                                          50.88                           
                                               5.69                       
                                                   14.51                  
                         (dec.)           (50.43                          
                                               5.64                       
                                                   14.70)                 
17  CH CH S  6-CH.sub.3                                                   
                 7-C.sub.5 H.sub.11                                       
                      H  206-208                                          
                              C.sub.14 H.sub.20 ClN.sub.3 OS              
                                          53.39                           
                                               6.30                       
                                                   13.63                  
                         (dec.)           (53.58                          
                                               6.42                       
                                                   13.39)                 
18   CH                                                                   
       CH S  (CH.sub.2).sub.4                                             
                      CH.sub.3                                            
                         240-245                                          
                              C.sub.13 H.sub.15 ClN.sub.3 OS              
                                          52.43                           
                                               5.42                       
                                                   14.11                  
                         (dec.)           (52.24                          
                                               5.51                       
                                                   14.02)                 
19  CH CH S  (CH.sub.2).sub.4                                             
                      C.sub.2 H.sub.5                                     
                         220-225                                          
                              C.sub.14 H.sub.17 ClN.sub.3 OS              
                                          53.92                           
                                               5.82                       
                                                   13.48                  
                         (dec.)           (53.81                          
                                               5.91                       
                                                   13.24)                 
__________________________________________________________________________
 *Melting Point of Hydrochloride
The infrared absorption spectrum and the nuclear magnetic resonance spectrum of all the compounds were found to be consistent with the chemical structure.
The compounds of the present invention have unique properties as blood platelet anti-aggregatory agents. These compounds are useful in the prevention of intravascular thrombosis, prevention of coronary thrombosis, prevention of transient ischemic episodes, prevention of platelet thrombosis in the use of prosthetic devices (artificial heart valves, etc.) and other thrombotic complications including thromboangitis obliterans, etc.
As stated as background of the present invention, optionally substituted imidazo[2,1-b]quinazolines reported by Beverung et al have a potent hypotensive activity which is undesirable side effect for anticlotting therapy. On the other hand, the compounds of the present invention do not have a hypotensive activity and more potent blood platelet antiaggregatory activity than imidazo[2,1-b]quinazolines.
EXAMPLE
The aggregometer method of Born [G. V. Born, Nature, 194, 927 (1962)] was used to assess the in vitro activity of the various compounds as to inhibition of adenosine diphosphate (ADP) and collagen (Coll) induced platelet aggregation. Platelet rich plasma (PRP) was separated by centrifugation from citrated (0.313%) rat blood.
A methanolic solution of the test compound was added to the PRP, then aggregation was induced by adding to the mixture of ADP solution containing CaCl2 or a collagen suspension prepared according to the method described by Ashida et al [S. Ashida and Y. Abiko, Thromb. Diath. Haemorrh., 30, 528 (1975)], and the optical density of the resulting mixture was determined. Control was made by addition of methanol instead of the above methanolic solution of the test compound, and the optical density of the resulting mixture was also determined, which showed 100% aggregation. A dose response curve was drawn from the results obtained above and the effective concentration giving a 50% inhibition (EC50) was calculated.
The blood pressure of normal rat was measured at 5-6 hours after the oral administration at a dose of 50 mg/kg.
The most preferred compound, 6-methyl-1,2,3,5-tetrahydroimidazo[2,1-b]quinazolin-2-one (BL-3459) reported by Beverung et al, was tested for the biological activities at the same time. Table I is illustrative of the blood platelet anti-aggregatory and hypotensive activities of some of the preferred embodiments of the present invention and BL-3459.
                                  TABLE I                                 
__________________________________________________________________________
Inhibition of Platelet Aggregation                                        
                  ex vivo*    Blood Pressure                              
Compound                                                                  
      in vitro (EC.sub.50)                                                
                  % Inhibition                                            
                              % Reduction                                 
No.   Coll (μM)                                                        
            ADP (μM)                                                   
                  at 50 mg/kg(p.o)in rat                                  
                              at 50 mg/kg(p.o)in rat                      
__________________________________________________________________________
1     1     5     84          5 ± 3                                    
4     15    19                                                            
6     1.9   4.2   24                                                      
8     0.1   5     57          8 ± 2                                    
9     15    20                                                            
11    10    85                                                            
14    3.5   17    32                                                      
15    2.2   3     90                                                      
16    0.08  0.58  60                                                      
17    0.19  2                                                             
18    0.60  48                                                            
BL-3459 0.8                                                               
      5     57    35 + 3                                                  
__________________________________________________________________________
 *ex vivo:                                                                
 Blood samples were collected 2 hours after oral administration of the    
 compound to be tested or vehicle alone. Platelet rich plasmas were       
 obtained by centrifugation of the blood. Platelet aggregation was induced
 by adding collagen suspension to the platelet rich plasma and was compare
 with that observed with the platelet rich plasma from the control rats   
 given vehicle alone.
A suitable dosage level for oral administration can range from about 0.5 to about 30 mg/kg in single or multiple doses along with an appropriate pharmaceutically acceptable carrier and diluent in the form of a tablet, a capsule or powder, if desired. The preferred dosage level of the compounds of the invention for adult human is in the range of about 10 to about 200 mg/day.
While the invention has been described in detail and with reference to specific embodiments thereof, it will be apparent to one skilled in the art that various changes and modifications can be made therein without departing from the spirit and scope thereof.

Claims (6)

What is claimed is:
1. A compound represented by the formula: ##STR13## wherein one of Z1,Z2 and Z3 is a sulfur atom and the remaining two of Z1, Z2 and Z3 represent CH, R1 and R2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, or a chlorine atom or, when Z1 or Z3 is a sulfur atom, R1 and R2 taken together can represent an alkylene chain of 3 to 5 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof.
2. A compound represented by the formula: ##STR14## wherein R1 and R2 each represents a hydrogen atom, an alkyl group having 1 to 5 carbon atoms, a phenyl group, a chlorine atom or, when taken together, R1 and R2 represent an alkylene chain of 3 to 5 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof.
3. A compound represented by the formula: ##STR15## wherein R1 and R2 each represents a hydrogen atom, an alkyl group or, when taken together, R1 and R2 represent an alkylene chain of 3 to 5 carbon atoms, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof.
4. A compound represented by the formula: ##STR16## wherein R1 and R2 each represents a hydrogen atom or an alkyl group, and R3 represents a hydrogen atom or an alkyl group having 1 to 5 carbon atoms, and a pharmaceutically acceptable acid addition salt thereof.
5. The compound of claim 2, wherein R1 and R2 jointly represent a tetramethylene group (--CH2 CH2 CH2 CH2 --), R3 is a hydrogen atom and the salt is hydrochloride.
6. The compound of claim 2, wherein R1 and R2 each represents a methyl group and the salt is hydrochloride.
US06/066,113 1978-08-11 1979-08-13 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones Expired - Lifetime US4284773A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP53-97832 1978-08-11
JP9783278A JPS5527105A (en) 1978-08-11 1978-08-11 Imidazothienopyrimidinones compound

Publications (1)

Publication Number Publication Date
US4284773A true US4284773A (en) 1981-08-18

Family

ID=14202683

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/066,113 Expired - Lifetime US4284773A (en) 1978-08-11 1979-08-13 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones

Country Status (16)

Country Link
US (1) US4284773A (en)
EP (1) EP0008408B1 (en)
JP (1) JPS5527105A (en)
AU (1) AU529068B2 (en)
CA (1) CA1116597A (en)
CS (1) CS219256B2 (en)
DE (1) DE2961552D1 (en)
DK (1) DK153844C (en)
ES (1) ES483289A1 (en)
GR (1) GR73839B (en)
IL (1) IL57923A (en)
MX (1) MX6242E (en)
PH (1) PH15530A (en)
SU (1) SU880252A3 (en)
YU (1) YU41170B (en)
ZA (1) ZA793909B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376121A (en) * 1980-06-27 1983-03-08 Hoffmann-La Roche Inc. Antiallerigically-active imidazothienopyrimidine derivatives

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4287340A (en) * 1979-08-27 1981-09-01 Warner-Lambert Company Dihydro-oxo-pyrido[1,2-a]thienopyrimidine compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US8304420B2 (en) 2006-11-28 2012-11-06 Shire Llc Substituted quinazolines for reducing platelet count
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
GB0808950D0 (en) * 2008-05-16 2008-06-25 Shire Llc Substituted quinazolines
EP3239170B1 (en) 2008-06-04 2019-03-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA3100941C (en) 2011-03-01 2024-03-05 Synergy Pharmaceuticals Inc. Process of preparing guanylate cyclase c agonists
WO2014131024A2 (en) 2013-02-25 2014-08-28 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
HRP20240805T1 (en) 2013-06-05 2024-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
CN114404588A (en) 2013-08-09 2022-04-29 阿德利克斯公司 Compounds and methods for inhibiting phosphate transport
CN114340631A (en) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 Combination for reducing serum phosphate in a patient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890321A (en) * 1971-09-20 1975-06-17 Pfizer 6-aryl-5-ethyl-pyrimidin-4-ol compounds useful as intermediates and bronchodilators
DE2411273A1 (en) 1974-03-06 1975-09-18 Schering Ag Thieno (2,3-d) pyrimidinone derivs - for use as anti-inflammatories and inters, for antimicrobials

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932407A (en) * 1973-11-19 1976-01-13 Bristol-Myers Company Optionally substituted 1,2,3,5-tetrahydroimidezo(2,1-b)-quinazolin-2-ones and 6(H)-1,2,3,4-tetrahydropyimido(2,1-b)quinazolin-2-ones

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890321A (en) * 1971-09-20 1975-06-17 Pfizer 6-aryl-5-ethyl-pyrimidin-4-ol compounds useful as intermediates and bronchodilators
DE2411273A1 (en) 1974-03-06 1975-09-18 Schering Ag Thieno (2,3-d) pyrimidinone derivs - for use as anti-inflammatories and inters, for antimicrobials

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Sauter et al., Monatsh. Chem. (1978), 109(1), 53-61. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376121A (en) * 1980-06-27 1983-03-08 Hoffmann-La Roche Inc. Antiallerigically-active imidazothienopyrimidine derivatives

Also Published As

Publication number Publication date
PH15530A (en) 1983-02-09
DE2961552D1 (en) 1982-02-04
DK336779A (en) 1980-02-12
ES483289A1 (en) 1980-09-01
DK153844B (en) 1988-09-12
IL57923A0 (en) 1979-11-30
DK153844C (en) 1989-01-30
MX6242E (en) 1985-01-28
SU880252A3 (en) 1981-11-07
IL57923A (en) 1982-09-30
JPS627914B2 (en) 1987-02-19
CA1116597A (en) 1982-01-19
AU4973579A (en) 1980-02-14
GR73839B (en) 1984-05-04
EP0008408A1 (en) 1980-03-05
AU529068B2 (en) 1983-05-26
CS219256B2 (en) 1983-03-25
YU41170B (en) 1986-12-31
EP0008408B1 (en) 1981-12-09
ZA793909B (en) 1980-10-29
JPS5527105A (en) 1980-02-27
YU194779A (en) 1983-10-31

Similar Documents

Publication Publication Date Title
US4284773A (en) 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones
EP0465254B1 (en) Fused thiophene compounds and uses thereof
CA1134362A (en) Benzimidazoles, their preparation and their use as pharmaceutical compositions
FI81351C (en) PROCEDURE FOR THE PHARMACOLOGICAL ACTIVATION OF ACTIVE 2-PYRIDYL SUBSTITUTES 6,7-DIHYDRO-3H, 5H-PYRROLO / 2,3-F / BENZIMIDAZOLE-6-ONER O-6-TIONER.
US4954498A (en) Tricyclic benzimidazole compounds, pharmaceutical compositions and methods of use
EP0091241A2 (en) Condensed pyrrolinone derivatives, and their production
CA1182458A (en) Derivatives of 5,6,7,7a-tetrahydro-4h-thieno- ¬3,2,-c|pyridin-2-one, preparation and use
US4193997A (en) Thieno[2,3-c] and [3,2-c]pyridines, process for their preparation and therapeutic applications thereof
CA1321201C (en) Benzothiepino[5,4-c]pyridazine compounds and their pharmaceutical uses
US3627766A (en) 5,6,7,8-TETRAHYDRO-PYRIDO{8 4{40 ,3{40 :4,5{9 THIENO{8 2,3-d{9 PYRIMIDINES
Abdel-Rahman et al. SYNTHESIS OF SOME NEW THIENO [2, 3-b] PYRIDINES, PYRIDO [3′, 2′: 4, 5]-THIENO [3, 2-d] PYRIMIDINES AND PYRIDO [3′, 2′: 4, 5] THIENO [3, 2-d][1, 2, 3]-TRIAZINES
US3636041A (en) 4 5-dihydro-7h-thieno(2 3-c)thiopyrans
US5021445A (en) Compounds useful for the treatment of hypoglycemia
Nakazumi et al. Synthesis of 4, 10‐dihydro‐4, 10‐dioxo‐1H [1] benzothiopyrano [3, 2‐B] pyridine and 7‐oxo‐7, 13‐dihydro [1] benzothiopyrano [2, 3‐b]‐1, 5‐benzodiazepine
US4352931A (en) Lin-benzoaminopurinols
US3723466A (en) Tricyclic compounds
US4843075A (en) Benzothiopyrano[4,3-c]pyridazine compounds, methods for preparing said compounds and uses of said compounds
US4124766A (en) Substituted 3-(4-imidazolylmethylene)carbazic and thiocarbazic acid esters
CA1095524A (en) Antiinflammatory imidazothiazoles
PT97570A (en) Process for the preparation of benzothienopyridine derivatives
US4725306A (en) Pyridinecarboxamide plant growth inhibitors
US4500708A (en) Benzothiazine derivatives
US4599409A (en) Bisamidine derivatives of 5,10-dioxo-4,5,9,10-tetrahydro-4,9-dioxopyrenes, of 6(5H)-phenanthridones, and of phenanthridines, useful as chemotherapeutic agents
IE64209B1 (en) New indole derivatives process for preparing them and pharmaceutical compositions containing them
NO169388B (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 5-AMINO-1,2-DITIOL-3-UNDIVATIVES

Legal Events

Date Code Title Description
AS Assignment

Owner name: DAIICHI SEIYAKU CO., LTD., NO. 14-10, NIHONBASHI 3

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:ISHIKAWA FUMIYOSHI;ASHIDA SHINICHIRO;REEL/FRAME:003847/0014

Effective date: 19790725

STCF Information on status: patent grant

Free format text: PATENTED CASE